Table 2:
Clinical outcomes, stratified by LR-3 vs. LR-4 category
| 8h | Number of Observations | HCC at 6 months (%) | HCC at 12 months (%) | Total Proportion with HCC | Total Proportion with LR4 | Median time to HCC (months) | % Downgraded |
|---|---|---|---|---|---|---|---|
| LR-3 Observations | |||||||
| Choi 2013 | 69 | 1.4% | 4.3% | 4.3% | 1.4% | 16.0% | |
| Tang 2019 | 53 | 30.2% | 32.1% | 6.1 (IQR 4.6 – 13.1) | |||
| Ojeda 2021 | 20.4% | 24.5% | 8.0% | 6.4 | |||
| Tanabe 2016 | 166 | 0% | 1.2% | 4.2% | 4.8% | 68.0% | |
| Hong 2019 | 186 | 7.0% | 11.0% | 8.6% | 17.7% | 16.0% | |
| Arvind 2022 | 458 | 5.1% | 12.5% | 24.1% | |||
| Agnello 2020 | 55 | 1.8% | 9.1% | 30.9% | 5.5% | 27.2 (range 5.3-56.1) | 52.0% |
| Kim 2020 | 38 | 5.3% | 4.4% | 15.8% | |||
| Smereka 2020 | 257 | 44.4% | |||||
| Ranathunga 2022 | 36 | 11.1% | 22.2% | 25.0 – 30.6% | |||
| Tang 2017 | 57 | 36.5% | 45.9 | ||||
| Xing 2018 | 71 | 18.3% | 8.5% | 25.4% | |||
| LR-4 Observations | |||||||
| Tang 2019 | 37 | 56.8% | N/A | 4.7 (IQR 2.5 – 14.5) | |||
| Sofue 2017 | 181 | 30.9% | N/A | 5.1 | 42.0% | ||
| Tanabe 2016 | 52 | 28.8% | 30.8% | 36.5% | N/A | 17.0% | |
| Hong 2019 | 133 | 32.0% | 44.0% | 33.1% | N/A | 20.0% | |
| Agnello 2020 | 19 | 10.5% | 31.6% | 42.1% | N/A | 19.4 (range 3.2 - 65.5) | 37.0% |
| Kim 2020 | 68 | 35.3% | 39.7% | 54.4% | N/A | ||
| Smereka 2020 | 83 | 69.9% | N/A | ||||
| Tang 2017 | 38 | 71.0% | N/A | 10.9 | |||
| Xing 2018 | 32 | 46.9% | N/A | 6.3% | |||